Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Optiray 320 mgI/mL and Visipaque 320 mgI/mL on Renal Function in Subjects With Stable Reduced Renal Function Undergoing Contrast-enhanced Computed Tomography

NCT00793182 is registered in ClinicalTrials.gov with Guerbet as lead sponsor.

NCT NCT00793182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00793182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Optiray 320 mgI/mL and Visipaque 320 mgI/mL on Renal Function in Subjects With Stable Reduced Renal Function Undergoing Contrast-enhanced Computed Tomography
Lead sponsor
Guerbet
Phase
Phase 4
Overall status
Terminated
Start date
January 31, 2009
Completion date
June 30, 2009
Enrollment
6 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment